<DOC>
	<DOCNO>NCT01053429</DOCNO>
	<brief_summary>This regulatory-required non-interventional pharmacovigilance study explore safety profile ziprasidone HCL monohydrate 20mg , 40mg , 60mg , 80mg real world patient population , thus , safety ( and/or efficacy ) signal check every visit contract study period maximum study end date , per protocol , April 2010 .</brief_summary>
	<brief_title>A Non-Interventional Post-Marketing Surveillance Study Evaluate Safety Efficacy Zeldox Capsule</brief_title>
	<detailed_description>All patient diagnose schizophrenia acute manic mixed episode associate bipolar disorder , without psychotic feature include study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Patients diagnose schizophrenia Patients know hypersensitivity ingredient product Patients recent acute myocardial infarction Patients uncompensated heart failure Patients condition potential increase QT interval ( QTinterval prolongation history QT prolongation ; congenital long QT syndrome ; use drug know increase QT interval ; arrhythmia treat class I III antiarrhythmic drug )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Regulatory Post-Marketing Surveillance</keyword>
	<keyword>Regulatory Pharmacovigilance</keyword>
	<keyword>ziprasidone</keyword>
</DOC>